Drug Information
Drug (ID: DG01598) and It's Reported Resistant Information
| Name |
FIIN-1
|
||||
|---|---|---|---|---|---|
| Synonyms |
FIIN-1; 1256152-35-8; CHEMBL2216830; N-(3-((3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-(4-(diethylamino)butylamino)-2-oxo-3,4- dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)methyl)phenyl)acrylamide; N-(3-{[3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-{[4-(diethylamino)butyl]amino}-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl]methyl}phenyl)prop-2-enamide; FIIN1; SCHEMBL17010767; BDBM50403060; ZINC95564544; NCGC00378818-01; HY-15813; CS-0009282; N-[3-[[3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[4-(diethylamino)butylamino]-2-oxo-4H-pyrimido[4,5-d]pyrimidin-1-yl]methyl]phenyl]prop-2-enamide
Click to Show/Hide
|
||||
| Structure |
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
| Formula |
15
|
||||
| IsoSMILES |
CCN(CC)CCCCNC1=NC=C2CN(C(=O)N(C2=N1)CC3=CC(=CC=C3)NC(=O)C=C)C4=C(C(=CC(=C4Cl)OC)OC)Cl
|
||||
| InChI |
InChI=1S/C32H39Cl2N7O4/c1-6-26(42)37-23-13-11-12-21(16-23)19-41-30-22(18-36-31(38-30)35-14-9-10-15-39(7-2)8-3)20-40(32(41)43)29-27(33)24(44-4)17-25(45-5)28(29)34/h6,11-13,16-18H,1,7-10,14-15,19-20H2,2-5H3,(H,37,42)(H,35,36,38)
|
||||
| InChIKey |
DNVFTXQYIYFQBW-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Type(s) of Resistant Mechanism of This Drug
ADTT: Aberration of the Drug's Therapeutic Target
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | |||||||||||||
|
Aberration of the Drug's Therapeutic Target (ADTT)
|
|||||||||||||
| Key Molecule: Fibroblast growth factor receptor 1 (FGFR1) | [1] | ||||||||||||
| Sensitive Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | ||||||||||||
| Molecule Alteration | Missense mutation | p.V561M (c.1681G>A) |
|||||||||||
| Wild Type Structure | Method: X-ray diffraction | Resolution: 1.63 Å | |||||||||||
| Mutant Type Structure | Method: X-ray diffraction | Resolution: 1.96 Å | |||||||||||
| Download The Information of Sequence | Download The Structure File | ||||||||||||
-
-
M
G
V
A
A
G
G
460
|
V
V
S
S
E
E
Y
Y
E
E
L
L
P
P
E
E
D
D
P
P
470
|
R
R
W
W
E
E
L
L
P
P
R
R
D
D
R
R
L
L
V
V
480
|
L
L
G
G
K
K
P
P
L
L
G
G
E
E
G
G
A
A
F
F
490
|
G
G
Q
Q
V
V
V
V
L
L
A
A
E
E
A
A
I
I
G
G
500
|
L
L
D
D
K
K
D
D
K
K
P
P
N
N
R
R
V
V
T
T
510
|
K
K
V
V
A
A
V
V
K
K
M
M
L
L
K
K
S
S
D
D
520
|
A
A
T
T
E
E
K
K
D
D
L
L
S
S
D
D
L
L
I
I
530
|
S
S
E
E
M
M
E
E
M
M
M
M
K
K
M
M
I
I
G
G
540
|
K
K
H
H
K
K
N
N
I
I
I
I
N
N
L
L
L
L
G
G
550
|
A
A
C
C
T
T
Q
Q
D
D
G
G
P
P
L
L
Y
Y
V
V
560
|
I
I
V
M
E
E
Y
Y
A
A
S
S
K
K
G
G
N
N
L
L
570
|
R
R
E
E
Y
Y
L
L
Q
Q
A
A
R
R
R
R
P
P
P
P
580
|
G
G
L
L
E
E
Y
Y
S
S
Y
Y
N
N
P
P
S
S
H
H
590
|
N
N
P
P
E
E
E
E
Q
Q
L
L
S
S
S
S
K
K
D
D
600
|
L
L
V
V
S
S
C
C
A
A
Y
Y
Q
Q
V
V
A
A
R
R
610
|
G
G
M
M
E
E
Y
Y
L
L
A
A
S
S
K
K
K
K
C
C
620
|
I
I
H
H
R
R
D
D
L
L
A
A
A
A
R
R
N
N
V
V
630
|
L
L
V
V
T
T
E
E
D
D
N
N
V
V
M
M
K
K
I
I
640
|
A
A
D
D
F
F
G
G
L
L
A
A
R
R
D
D
I
I
H
H
650
|
H
H
I
I
D
D
Y
Y
Y
Y
K
K
K
K
T
T
T
T
N
N
660
|
G
G
R
R
L
L
P
P
V
V
K
K
W
W
M
M
A
A
P
P
670
|
E
E
A
A
L
L
F
F
D
D
R
R
I
I
Y
Y
T
T
H
H
680
|
Q
Q
S
S
D
D
V
V
W
W
S
S
F
F
G
G
V
V
L
L
690
|
L
L
W
W
E
E
I
I
F
F
T
T
L
L
G
G
G
G
S
S
700
|
P
P
Y
Y
P
P
G
G
V
V
P
P
V
V
E
E
E
E
L
L
710
|
F
F
K
K
L
L
L
L
K
K
E
E
G
G
H
H
R
R
M
M
720
|
D
D
K
K
P
P
S
S
N
N
C
C
T
T
N
N
E
E
L
L
730
|
Y
Y
M
M
M
M
M
M
R
R
D
D
C
C
W
W
H
H
A
A
740
|
V
V
P
P
S
S
Q
Q
R
R
P
P
T
T
F
F
K
K
Q
Q
750
|
L
L
V
V
E
E
D
D
L
L
D
D
R
R
I
I
V
V
A
A
760
|
L
L
T
T
S
S
N
N
Q
Q
E
E
|
|||||||||||||
| Experimental Note | Revealed Based on the Cell Line Data | ||||||||||||
| In Vitro Model | Ba/F3 cells | Colon | Homo sapiens (Human) | CVCL_0161 | |||||||||
| Experiment for Drug Resistance |
CellTiter-Glo Luminescent Cell Viability Assay | ||||||||||||
| Mechanism Description | The missense mutation p.V561M (c.1681G>A) in gene FGFR1 cause the sensitivity of FIIN-1 by aberration of the drug's therapeutic target | ||||||||||||
Endometrial cancer [ICD-11: 2C76]
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
Aberration of the Drug's Therapeutic Target (ADTT)
|
||||
| Key Molecule: Fibroblast growth factor receptor 2 (FGFR2) | [1] | |||
| Sensitive Disease | Endometrial adenocarcinoma [ICD-11: 2C76.0] | |||
| Molecule Alteration | Missense mutation | p.N549K (c.1647T>G) |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| In Vitro Model | Ba/F3 cells | Colon | Homo sapiens (Human) | CVCL_0161 |
| Experiment for Drug Resistance |
CellTiter-Glo Luminescent Cell Viability Assay | |||
| Mechanism Description | The missense mutation p.N549K (c.1647T>G) in gene FGFR2 cause the sensitivity of FIIN-1 by aberration of the drug's therapeutic target | |||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.